Anna Lyssette is evaluating the performance of two biotechnology companies: Biotech Holdings and Advanced Biotech. Both companies released their first new drugs early in the year, but Lyssette is worried about a possible lack of comparability due to differing strategies. Biotech Holdings acquired the research and development for its drug from another company while Advanced Biotech developed its drug internally. In the current accounting period, all else equal, Biotech Holdings would most likely report

a. lower total assets.

b. higher net income.

c. similar cash flow from operations.